THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 111 filers reported holding THERAVANCE BIOPHARMA INC in Q2 2021. The put-call ratio across all filers is 0.38 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $252,272 | -26.2% | 29,232 | -11.4% | 0.15% | -24.3% |
| Q2 2023 | $341,643 | +14.6% | 33,009 | +20.2% | 0.20% | +23.2% |
| Q1 2023 | $298,071 | -1.6% | 27,472 | +1.8% | 0.16% | +3.8% |
| Q4 2022 | $302,817 | +8.5% | 26,989 | -1.9% | 0.16% | +42.3% |
| Q3 2022 | $279,000 | +13.4% | 27,509 | +1.5% | 0.11% | +22.0% |
| Q2 2022 | $246,000 | -29.3% | 27,109 | -25.4% | 0.09% | -41.7% |
| Q1 2022 | $348,000 | -13.4% | 36,359 | 0.0% | 0.16% | +2.6% |
| Q4 2021 | $402,000 | +122.1% | 36,359 | +49.0% | 0.15% | +90.0% |
| Q3 2021 | $181,000 | -53.2% | 24,402 | -8.4% | 0.08% | -49.7% |
| Q2 2021 | $387,000 | -42.3% | 26,643 | -18.9% | 0.16% | -43.8% |
| Q1 2021 | $671,000 | +18.1% | 32,871 | +2.8% | 0.28% | +19.9% |
| Q4 2020 | $568,000 | +66.1% | 31,966 | +38.1% | 0.24% | +31.8% |
| Q3 2020 | $342,000 | -23.1% | 23,148 | +9.2% | 0.18% | -15.2% |
| Q2 2020 | $445,000 | -28.6% | 21,198 | -21.3% | 0.21% | -17.6% |
| Q1 2020 | $623,000 | -17.6% | 26,943 | -7.8% | 0.26% | +106.5% |
| Q4 2019 | $756,000 | -10.6% | 29,216 | -32.7% | 0.12% | -27.1% |
| Q3 2019 | $846,000 | +2.1% | 43,442 | -14.4% | 0.17% | -2.9% |
| Q2 2019 | $829,000 | +27.7% | 50,751 | +77.4% | 0.18% | -87.3% |
| Q1 2019 | $649,000 | +13.1% | 28,612 | +27.5% | 1.38% | +1309.2% |
| Q4 2018 | $574,000 | -45.5% | 22,443 | -30.4% | 0.10% | -10.1% |
| Q3 2018 | $1,053,000 | +54.4% | 32,226 | +7.2% | 0.11% | -81.9% |
| Q2 2018 | $682,000 | -14.8% | 30,055 | -8.9% | 0.60% | -13.1% |
| Q1 2018 | $800,000 | -17.9% | 32,989 | -5.6% | 0.69% | -43.2% |
| Q4 2017 | $974,000 | +2.9% | 34,929 | +26.3% | 1.22% | +854.7% |
| Q3 2017 | $947,000 | -14.0% | 27,646 | 0.0% | 0.13% | -22.0% |
| Q2 2017 | $1,101,000 | -10.6% | 27,646 | -17.4% | 0.16% | -25.1% |
| Q1 2017 | $1,232,000 | +27.8% | 33,454 | +10.6% | 0.22% | -24.0% |
| Q4 2016 | $964,000 | -4.5% | 30,237 | +8.7% | 0.29% | -41.0% |
| Q3 2016 | $1,009,000 | +82.8% | 27,829 | +14.4% | 0.49% | +19.0% |
| Q2 2016 | $552,000 | -22.1% | 24,323 | -35.5% | 0.41% | -58.0% |
| Q1 2016 | $709,000 | – | 37,703 | – | 0.98% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Link Fund Solutions Ltd | 5,251,349 | $135,459,000 | 69.86% |
| Chescapmanager LLC | 949,006 | $24,570,000 | 3.61% |
| Baupost Group | 9,309,168 | $241,014,000 | 2.66% |
| Rock Springs Capital Management LP | 655,200 | $16,963,000 | 0.54% |
| Rubric Capital Management LP | 173,400 | $4,489,000 | 0.51% |
| Newtyn Management, LLC | 173,300 | $4,487,000 | 0.41% |
| NJ State Employees Deferred Compensation Plan | 38,142 | $988,000 | 0.17% |
| King Wealth Management Group | 22,500 | $583,000 | 0.15% |
| Virtus ETF Advisers LLC | 29,216 | $756,000 | 0.12% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 452,615 | $11,718,000 | 0.12% |